Glenmark To Debut Ryaltris In Australia
Rhinitis Therapy Gets TGA Nod For Launch In 2020
Glenmark ended 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.
You may also be interested in...
Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.
Glenmark has struck the latest in a series of commercialization deals for its Ryaltris nasal spray in the form of a ten-year alliance with Bausch Health for the Canadian market.
Glenmark has struck a marketing deal with Menarini to commercialize the Indian firm’s Ryaltris nasal spray in 33 countries across Europe. The agreement adds to a network of licenses already in place across the world.